We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Latest News

News

DxS Signs a License with DiagnoCure for its Scorpions® Technology

DiagnoCure will gain access to Scorpions for the development of their GCC-based molecular test for colorectal cancer.
News

IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA

IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
News

Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer

Eden will manufacture MBP-DC-SIGN for Borean to use in key preclinical studies.
News

Increased Risk for Arthritis and Lupus Tied to new Gene

Scientists identify a critical gene that increases a person’s risk for rheumatoid arthritis and systemic lupus and may be involved in other autoimmune diseases.
News

Celera to Acquire Berkeley HeartLab

Acquisition provides Celera with CLIA-certified laboratory to commercialize its portfolio of new tests & vehicle to deliver personalized disease management in cardiovascular disease.
News

Philips and the Institute of Health Sciences Join Forces in Molecular Medicine

Royal Philips Electronics and IHS will create new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment.
News

Agendia Raises €25 Million and Receives Second FDA Clearance

ING, one of the largest bank-insurers, becomes a shareholder of Agendia.
News

Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada

Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
News

BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University

BSD Medical gains exclusive rights to Duke’s treatment system for primary breast cancer using hyperthermia therapy.
News

A Study by the MUHC and McGill University Opens a new Door to Understanding Cancer

Study provides a key to understand the mechanisms that trigger cancer cell growth that may prove crucial to develop more targeted treatments for cancer.
Advertisement